Navigation Links
Faust Pharmaceuticals' Phase IIa Results for Parkinson's Disease,Presented at International Congress of Parkinson's Disease and,Movement Disorders

tely, we hope to demonstrate that FP0011 can be a potent, safe glutamate release inhibitor that could have a role in other neurological diseases and conditions where excess glutamate has been implicated, such as Alzheimer's disease, ALS, Huntington's disease, multiple sclerosis and neuropathy."

About Parkinson's disease Parkinson's disease affects both men and women in almost equal numbers with no apparent social, ethnic, economic or geographic links. In the United States, it is estimated that 60,000 new cases are diagnosed each year, joining the 1.5 million Americans who currently have Parkinson's disease. While the condition usually develops after the age of 65, 15% of those diagnosed are under 50. Estimates range up to about 1,200,000 patients in Europe.

About Faust Pharmaceuticals - www.faustpharma.com Faust Pharmaceuticals is a clinical stage products company specializing in the discovery and development of drugs for diseases of the nervous system. The company's lead compound, FP0011, is a small molecule glutamate inhibitor in Phase II for Parkinson's disease and ALS. A second compound, FP0023, is a fetal gene activating utrophin inducer in preparation for Phase I/II for Duchenne Muscular Dystrophy. The company additionally has pre-clinical programs on targets such as mGluR (metabotropic glutamate receptor), as well as a proprietary drug discovery platform targeting GPCRs (G-Protein Coupled Receptors).

For further information, please contact:
Andrew Lloyd & Associates Andrew Lloyd / Neil Hunter Tel: +44 1273 675100 allo@ala.com>allo@ala.com / neil@ala.com>neil@ala.com

Katie Ollerenshaw ANDREW LLOYD & ASSOCIATES http://www.ala.com




Page: 1 2 3 4

Related medicine technology :

1. Data from Rexahn Pharmaceuticals Phase I Trial of RX-0201 (Archexin) to Be Presented at the 43rd American Society of Clinical Oncology Annual Meeting in Chicago
2. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
3. Aeolus Pharmaceuticals AEOL 10113 May Play an Important Role Regulating the Oxidative Damage Induced by Ionizing Radiation
4. Aeolus Pharmaceuticals AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy
5. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
6. ACADIA Pharmaceuticals Schizophrenia Programs to Be Presented at the 2007 International Congress on Schizophrenia Research
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:5/21/2013)... Fla. , May 21, 2013  Janssen ... safety results from the global Phase 3 PROMISE ... inhibitor simeprevir (TMC435) led to sustained virologic response ... in 79 percent of treatment-experienced genotype 1 chronic ... including all stages of liver fibrosis, when administered ...
(Date:5/21/2013)... , May 21, 2013 Abaxis, Inc. (NasdaqGS: ... systems, announced today that Martin Mulroy ... Stifel Annual Dental & Veterinary Conference on Wednesday, May ... be held at Le Parker Meridien Hotel in ... Abaxis Abaxis develops, manufactures, markets and sells ...
(Date:5/21/2013)...  BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC ... stem cell based therapies for various personal applications, announced ... and CEO, will be presenting at the Marcum MicroCap ... on Thursday, May 30, 2013 at the Grand Hyatt ... York City.  Mr. Weinreb,s presentation will take place at ...
Breaking Medicine Technology:Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3
... July 19, 2011 Jonah and Dina Shacknai today issued the ... of police reports by the Paradise Valley Police Department: ... us had hoped, it did produce a wonderful son, Max, whom ... police reports are not reflective of the totality or the precise ...
... power of cosmetic lasers has grown by leaps and bounds ... laser treatments were first used, they were ablative lasers that ... younger skin below. However, the drawback to these early cosmetic ... of the skin down, which they did by stripping the ...
Cached Medicine Technology:Renaissance Laser and Vein Institute Specializes in Revolutionary Laser Treatments for a Variety of Cosmetic Applications 2
(Date:5/21/2013)... NC (PRWEB) May 21, 2013 A ... CELLS Translational Medicine indicates that stem cells harvested from ... bone marrow in helping to modulate the body’s immune ... in developing new stem-cell-based therapies, as adipose tissue-derived stem ... than those found in bone marrow and can be ...
(Date:5/21/2013)... May 21, 2013 The American Diabetes ... people in the United States of America are affected ... at a great risk of developing peripheral neuropathy which ... lives. The ADA further goes on saying that the ... and around 2 million new cases are diagnosed every ...
(Date:5/21/2013)... Australia (PRWEB) May 22, 2013 About ... made the Fertility Clinics industry one of ... industry assists patients who are unable to conceive naturally ... and popular of which is in-vitro fertilisation (IVF) cycles. ... IVF cycles in Australia has increased by 4.4% per ...
(Date:5/21/2013)... News) -- Aggressive treatment for prostate cancer may ... underlying medical conditions, a new study finds. ... and radioactive seed implants, can cause serious side ... bowel problems, explained researchers from the University of ... that older patients with slower growing forms of ...
(Date:5/21/2013)... announced today that it is a Grand Challenges ... & Melinda Gates Foundation. Tae Seok Moon, PhD, ... will pursue an innovative global health and development ... by Probiotic Organisms." , Grand Challenges Explorations (GCE) ... break the mold in how we solve persistent ...
Breaking Medicine News(10 mins):Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 2Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 3Health News:Neuracel Aims to Reduce Peripheral Neuropathy Pain 2Health News:Fertility Clinics in Australia Industry Market Research Report Now Available from IBISWorld 2Health News:Fertility Clinics in Australia Industry Market Research Report Now Available from IBISWorld 3Health News:Age, Other Illnesses May Make Prostate Cancer Treatment Unnecessary 2Health News:Gates Fellowship addresses parasite infection in developing world 2
... efforts to unlock therapeutic potential , , MONDAY, Feb. 9 ... Obama,s anticipated lifting of the eight-year ban on embryonic ... W. Bush. , The anticipation moved one step closer ... House Democrats at a closed-door Virginia retreat a "guarantee" ...
... Inc. (Nasdaq: BNVI ) announced today the ... company,s Scientific Advisory Board. Dr. Gustafsson has extensive experience ... biotech companies. "We are very excited to have Dr. ... advancing our discovery platforms," said Isaac Cohen, O.M.D., Bionovo,s ...
... Fla., Feb. 9 MEDai, Inc., a leading provider ... it is offering a free case study on its ... analytic solution Risk Navigator Clinical(R) and its,application to keep ... The case study explores how one of MEDai,s ...
... -- Mindray Medical,International Limited (NYSE: MR ... devices worldwide, today announced that it will report ... year ended December 31,2008, after the U.S. market ... an earnings conference call at 8:00 AM on ...
... during 2008 holiday shopping seasonFORT WORTH, Texas, Feb. 9 ... customers, raised nearly $1.5 million for the fifth-annual ... fundraising initiative for St. Jude Children,s Research Hospital that ... , Customers who shopped at RadioShack stores had the ...
... supplement is the real deal. Extreme Endurance is a 100% ... certified drug-free by the world,s largest sports drug laboratory. In a ... lactic acid was reduced by 15%. This was a 30 day ... ...
Cached Medicine News:Health News:Scientists Heartened at Prospect of End to Stem Cell Ban 2Health News:Scientists Heartened at Prospect of End to Stem Cell Ban 3Health News:Jan Ake Gustafsson, M.D., Ph.D., Joins Bionovo's Scientific Advisory Board 2Health News:Jan Ake Gustafsson, M.D., Ph.D., Joins Bionovo's Scientific Advisory Board 3Health News:Jan Ake Gustafsson, M.D., Ph.D., Joins Bionovo's Scientific Advisory Board 4Health News:Health Plans Use MEDai to Forecast, Rank Risk and Drive Interventions 2Health News:Mindray to Report Fourth Quarter and Fiscal Year 2008 Financial Results on March 4, 2009 2Health News:RadioShack Helps Raise $1.5 Million for St. Jude Children's Research Hospital(R) Fifth-Annual Thanks and Giving(R) Campaign 2Health News:RadioShack Helps Raise $1.5 Million for St. Jude Children's Research Hospital(R) Fifth-Annual Thanks and Giving(R) Campaign 3Health News:Nutritionist Investigates Claims of New Sports Nutritional Supplement 2Health News:Nutritionist Investigates Claims of New Sports Nutritional Supplement 3Health News:Nutritionist Investigates Claims of New Sports Nutritional Supplement 4Health News:Nutritionist Investigates Claims of New Sports Nutritional Supplement 5
... This comprehensive guide provides ... drug administration information in a ... revised 2006 edition includes the ... FDA with key nursing implications ...
Alphabetically organized monographs on more than 1,000 generic and 3,000 trade name drugs....
Nursing2006 Drug Handbook Entries include Alerts, dosage adjustments for specific populations, I.V. administration, off-label indications, adverse reactions, and more....
The mission of AHFS DI Essentials (American Hospital Formulary Service) is to provide an evidence-based foundation for safe and effective drug therapy....
Medicine Products: